Workshop on the production, application and clinical translation of "non-s standard" PET nudides: A meeting report

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 2, 2008, Pages 101-106

  Lewis, J S ^a   Welch, M J ^a   Tang, L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Emission computed; Radioisotopes; Radiopharmaceuticals; Tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 124; (3 IODOBENZYL)GUANIDINE I 131; 4 BROMODEXETIMIDE BR 76; ARSENIC 72; ARSENIC 74; ASPARAGINE CU 64; BROMINE 76; CITRIC ACID Y 86; COPPER 60; COPPER 61; COPPER 64; COPPER CHLORIDE; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; ETHYLENEDIAMINE TETRAMETHYLENEPHOSPHONIC ACID Y 86; GALLIUM 66; IDOXURIDINE I 124; IODINE 124; MONOCLONAL ANTIBODY; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 94M; TITANIUM 45; TRACER; YTTRIUM 86; YTTRIUM 90; ZIRCONIUM 89;

CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; CYCLOTRON; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG DISTRIBUTION; EDITORIAL; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MEDICAL RESEARCH; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIMARY BILIARY CIRRHOSIS; PUBLICATION; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TEMPORAL LOBE EPILEPSY; THYROID CARCINOMA; UTERINE CERVIX CANCER; WILSON DISEASE;

IMAGE ENHANCEMENT; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 44249097811     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Guidance for industry, investigators, and reviewers exploratory IND studies [homepage on the Internet]. Rockville, MD, USA: U.S. Food and Drug Administration. Available from: http://www.fda.gov/CDER/guidance/ 7086fnl.htm.
2. Linder MC. Biochemistry of copper. New York: Plenum Press; 1991.
3. 6OCu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55:1233-8.
4. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
5. 64Cu-TETA-octreotide as PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21.
6. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818-24.
7. 2] in patients with colorectal cancers. J Nucl Med 1995;36:9P.
8. 67Cu-21T-BATLYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998;18:2779-88.
9. DeNardo GL, DeNardo SJ, Meares CF, Kukis D, Diril H, McCall MJ et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibodies Immunconj Radiopharm 1991;4:777-85.
10. 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533-41.
11. DeNardo S, DeNardo G, Kukis D, Mausner L, Moody D, Meares C. Pharmacology of Cu-67-TETA-Lym-1 antibody in patients with B cell lymphoma. Antibody Immunoconj Radiopharms 1991;4:36.
12. 67Cu-2IT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 1999; 40:2014-20.
13. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med 2002;29:821-30.
14. 76Br]4-bromodexetimide. J Nucl Med 1999;40:935-41.
15. 77Br]bromoestradiol: dosimetry and preliminary clinical studies. J Nucl Med 1982;23:425-30.
16. Eschmann SM, Reischl G, Bilger K, Kupferschläger J, Thelen MH, Dohmen BM et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. EurJ Nucl Med Mol Imaging 2002;29:760-7.
17. Freudenberg LS, Antoch G, Görges R, Knust J, Pink R, Jentzen W et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiology 2003;13:L19-L23.
18. 124I. J Clin Endocrin Metab 1986;63:918-27.
19. 124I-mIBG positron emission tomography. BrJ Radiol 1992; 65:787-91.
20. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet Oncol 2001;358:729-29.
21. 124I]iododeoxyuridine. Cancer Res 2000;60:624-35.
22. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304-10.
23. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M et al. Molecular imaging and biological evaluation of HUMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
24. Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992;33:2020-3.
25. Rösch F, Herzog H, Plag C, Neumaier B, Braun U, Müller-Gärtnere HW et al. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med 1996; 23:958-66.
26. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1561-6.
27. 1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-8.